Carbonic anhydrase IX: A new druggable target for the design of antitumor agents

Medicinal Research Reviews

Volumn 28, Issue 3, 2008, Pages 445-463

  Winum, Jean Yves ^a   Rami, Marouan ^a   Scozzafava, Andrea ^b   Montero, Jean Louis ^a   Supuran, Claudiu ^b  

^a INSTITUT CHARLES GERHARDT   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticancer agents; Carbonic anhydrase IX; Drug design; Enzyme inhibitor; Sulfamate; Sulfamide; Sulfonamide

Indexed keywords

1 PENTAFLUOROPHENYLAMIDOINDANE 5 SULFONAMIDE; 1,10 DECYLENE DISULFAMATE; 1,8 OCTYLENE DISULFAMATE; 2 BUTYLAMIDOINDANE 5 SULFONAMIDE; 2 NONYLAMIDOINDANE 5 SULFONAMIDE; 4 (2 MERCAPTOPHENYLCARBOXAMIDE)BENZENESULFONAMIDE; 4 AMINOETHYLBENZENESULFONAMIDE DERIVATIVE; 4 CARBOHYDRAZIDOBENZENESULFONAMIDE DERIVATIVE; ACETAZOLAMIDE; BICARBONATE; BORON; BRINZOLAMIDE; CARBON DIOXIDE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; HYPOXIA INDUCIBLE FACTOR 1; INDISULAM; MAFENIDE; METHAZOLAMIDE; PHENYL 1,4 DIMETHYLENE DISULFAMATE; PHENYLSULFAMATE DERIVATIVE; PROTON; SULFAMIDE DERIVATIVE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; UNINDEXED DRUG; ZINC;

ACIDIFICATION; CARCINOGENESIS; CATALYSIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HYDRATION; HYPOXIA; METASTASIS; NEOPLASM; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REACTION ANALYSIS; REVIEW; STRUCTURE ANALYSIS; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42549148009     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20112     Document Type: Review

References (68)

1. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006;4:61-70.
2. Pastorekova S, Pastorek J. Cancer-related carbonic anhydrase isozymes. In: Supuran CT, Scozzafava A, Conway J, editors. Carbonic anhydrase - Its inhibitors and activators. Boca Raton (FL), USA: CRC Press; 2004. pp 253-280.
3. Supuran CT. Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 2007;7:825-833.
4. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-189.
5. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336-4350.
6. Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patents 2006;16:1627-1664.
7. Pastorekova S, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007;7:865-878.
8. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zatovicova M, Liao S, Portetelle D, Stanbridge EJ, Zavada J, Burny A, Kettmann R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putativehelix-loop-helix DNA binding segment. Oncogene 1994;9:2788-2888.
9. Opavský R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 1996;33:480-487.
10. Türeci O, Sahin U, Vollmar E, Siemer S, Gotten E, Seitz G, Parkkila AK, Shah GN, Grubb JH, Pfreundschuh M, Sly WS. Human carbonic anhydrase XII: cDNA cloning, expression and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers. Proc Natl Acad Sci USA 1998;95:7608-7613.
11. Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, Saarnio J, Pastorek J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398-408.
12. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160-6165.
13. Harris AL. Hypoxia - A key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
14. Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7.
15. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-7083.
16. Svastova E, Hulikova A, Rafajova M, Zatovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-445.
17. Cecchi A, Hulikova A, Pastorek J, Pastorekova S, Scozzafava A, Winum JY, Montero JL, Supuran CT. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834-4841.
18. Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc 2006;128:8329-8335.
19. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort M, Pastorekova S, Scozzafava A, Wouters BG, Lambin P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007;83:367-373.
20. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 2000;6:15-19.
21. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26:299-310.
22. Thiry A, Dogne JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566-573.
23. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006;42:167-216.
24. Svastova E, Zilka N, Zatovicova M, Gibadulinova A, Ciampor F, Pastorek J, Pastorekova S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003;290:332-345.
25. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993;13:1549-1556.
26. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg Med Chem 2001;9:703-714.
27. Supuran CT. Indisulam: An anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003;12:283-287.
28. Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:217-223.
29. Vullo D, Franchi M, Gallori E, Pastorek J, Scozzafava A, Pastorekova S, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003;13:1005-1009.
30. Ilies MA, Vullo D, Pastorek J, Scozzafava A, Ilies M, Caproiu MT, Pastorekova S, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J Med Chem 2003;46:2187-2196.
31. Franchi M, Vullo D, Gallori E, Pastorek J, Russo A, Scozzafava A, Pastorekova S, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J Enzyme Inhib Med Chem 2003;18:333-338.
32. Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869-873.
33. Garaj V, Pucetti L, Fasolis G, Winum J-Y, Montero J-L, Scozzafava A, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004;14:5427-5433.
34. Garaj V, Pucetti L, Fasolis G, Winum J-Y, Montero J-L, Scozzafava A, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102-3108.
35. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 2000;43:4542-4551.
36. Di Fiore A, De Simone G, Menchise V, Pedone C, Casini A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorg Med Chem Lett 2005;15:1937-1942.
37. Vullo D, Scozzafava A, Pastorekova S, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg Med Chem Lett 2004;14:2351-2356.
38. Cecchi A, Taylor SD, Liu Y, Hill B, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett 2005;15:5192-5196.
39. Puccetti L, Fasolis G, Vullo D, Chohan ZH, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and theirzinc complexes. Bioorg Med Chem Lett 2005;15:3096-3101.
40. Puccetti L, Fasolis G, Cecchi A, Winum J-Y, Gamberi A, Montero J-L, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg Med Chem Lett 2005;15:2359-2364.
41. Ozensoy O, Puccetti L, Fasolis G, Arslan O, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett 2005;15:4862-4866.
42. Cecchi A, Winum J-Y, Innocenti A, Vullo D, Montero J-L, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg Med Chem Lett 2004;14:5775-5780.
43. Innocenti A, Villar R, Martinez-Merino V, Gil MJ, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor- associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Bioorg Med Chem Lett 2005;15:4872-4876.
44. Winum JY, Dogne JM, Casini A, de Leval X, Montero JL, Scozzafava A, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J Med Chem 2005;48:2121-2125.
45. Thiry A, Ledecq M, Cecchi A, Dogné JM, Wouters J, Supuran CT, Masereel B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem 2006;49:2743-2749.
46. Winum JY, Cecchi A, Montero JL, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor- associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg Med Chem Lett 2005;15:3302-3306.
47. Winum JY, Scozzafava A, Montero JL, Supuran CT. Metal binding functions in the design of carbonic anhydrase inhibitors. Curr Top Med Chem 2007;7:835-848.
48. Winum JY, Scozzafava A, Montero JL, Supuran CT. Sulfamates and their therapeutic potential. Med Res Rev 2005;25:186-228.
49. Winum JY, Scozzafava A, Montero JL, Supuran CT. Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev 2006;26:767-792.
50. Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46:2197-2204.
51. Nussbaumer P, Billich A. Steroid sulfatase inhibitors. Med Res Rev 2004;24:529-576.
52. Nussbaumer P, Billich A. Steroid sulfatase inhibitors: Their potential in the therapy of breast cancer. Curr Med Chem Anticancer Agents 2005;5:507-528.
53. Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46:5471-5477.
54. Winum JY, Pastorekova S, Jakubickova L, Montero JL, Scozzafava A, Pastorek J, Vullo D, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett 2005;15:579-584.
55. Briganti F, Pierattelli A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors .37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. Eur J Med Chem 1996;31:1001-1010.
56. Casini A, Winum J-Y, Montero J-L, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II with sulfamide derivatives. Bioorg Med Chem Lett 2003;13:837-840.
57. Winum J-Y, Innocenti A, Nasr J, Montero J-L, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides - A new zinc-binding function in the design of inhibitors. Bioorg Med Chem Lett 2005;15:2353-2358.
58. Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D- glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett 2004;14:225-229.
59. Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G. Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg Med Chem Lett 2007;17:1726-1731.
60. Winum JY, Temperini C, El Cheikh K, Innocenti A, Vullo D, Ciattini S, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: Clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024-7031.
61. Winum JY, Thiry A, Cheikh KE, Dogne JM, Montero JL, Vullo D, Scozzafava A, Masereel B, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg Med Chem Lett 2007;17:2685-2691.
62. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Vullo D, Supuran CT, Poulsen SA. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J Med Chem 2007;50:1651-1657.
63. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Vullo D, Supuran CT, Poulsen SA. Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett 2007;17:987-992.
64. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA. A novel class of carbonic anhydrase inhibitors: Glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem 2006;49:6539-6548.
65. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: From concept to clinic. Clin Oncol 2007;19:427-442.
66. Boyle RG, Travers S. Hypoxia: Targeting the tumour. Anticancer Agents Med Chem 2006;6:281-286.
67. Saczewski F, Slawinski J, Kornicka A, Brzozowski Z, Pomarnacka E, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg Med Chem Lett 2006;16:4846-4851.
68. De Simone G, Vitale RM, Di Fiore A, Pedone C, Scozzafava A, Montero JL, Winum JY, Supuran CT. Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem 2006;49:5544-5551.